Maria C Ryan

US Patent:

6914057, Jul 5, 2005

Filed:

Sep 28, 1999

Appl. No.:

09/787866

Inventors:

Maria Emanuel Ryan - Huntington NY, US
Lorne M. Golub - Smithtown NY, US
Nungavaram S. Ramamurthy - Smithtown NY, US

Assignee:

The Research Foundation of State University of New York - Albany NY

International Classification:

A61K031/65

US Classification:

514152

Abstract:

Methods of reducing the risk of cataract development in a mammal are provided and include administering to the mammal an effective amount of a tetracycline derivative. A preferred tetracycline derivative administered according to the methods of the present invention is 6α-deoxy 5-hydroxy-4-dedimethylaminotetracycline.

US Patent:

59290552, Jul 27, 1999

Filed:

Jun 23, 1997

Appl. No.:

8/880945

Inventors:

Maria Emanuel Ryan - Huntington NY
Lorne M. Golub - Smithtown NY
Nungavaram S. Ramamurthy - Smithtown NY
Thomas F. McNamara - Port Jefferson NY

Assignee:

The Research Foundation of State University of New York - Albany NY

International Classification:

A61K 3165
A61K 3828
A61K 31155

US Classification:

514152

Abstract:

A method for treating diabetes in a mammal by moderately controlling blood glucose concentration in the mammal together with administering to the mammal an amount of a tetracycline compound effective to reduce complications associated with diabetic hyperglycemia. The method enables long term management of diabetes by avoiding the problems associated with tight control of blood glucose concentrations, i. e. , hypoglycemia tolerance and seizures, while simultaneously avoiding the problems associated with conventional moderate control of blood glucose concentrations, i. e. , pathological complications associated with hyperglycemia, such as nephropathy, retinopathy, etc. Blood glucose concentration can be controlled by moderate administration (e. g. , fewer injections per day) of insulin or another glucose-modulating agent, while pathological complications characteristic of diabetic hyperglycemia are ameliorated through the activity of tetracycline compound, the latter preferably administered in an amount that is substantially non-antimicrobial.